Revolution Medicines에 대한 매도 수량은 투자자에게 Revolution Medicines의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Revolution Medicines (NASDAQ:RVMD) 주식, 공매도 수량 보고

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

News

NIVF

NewGenIvf Group Receives Written Notice That Its Securities Are Subject To Delisting Due To Non-Compliance With Two Nasdaq Listing Rules

<p>Needham  analyst Scott Berg   reiterates Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Buy and maintains $20 price target.</p>


Price Target

Reiteration

Analyst Ratings

PYCR

Needham Reiterates Buy on Paycor HCM, Maintains $20 Price Target

<p>Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.03 by 200 percent. This is a 142.86 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $107.50 million which missed the analyst consensus estimate of $113.46 million by 5.25 percent. This is a 9.80 percent decrease over sales of $119.19 million the same period last year.</p>


DXLG

Destination XL Group Q3 EPS $(0.03) Misses $0.03 Estimate, Sales $107.50M Miss $113.46M Estimate

<p>The reverse stock split was approved by the Company's shareholders at a special meeting held on November 1, 2024.&nbsp;</p>


Stock Split

Global Mofy AI Resolves To Effect Reverse Stock Split Of Ordinary Shares, With Split Ratio Set At 1-For-15, Effective On November 26, 2024

<p>After a sharp decline on Thursday,&nbsp;<strong>MicroStrategy Inc.</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is showing signs of recovery in pre-market trading on Friday.</p>
<p><strong>What Happened</strong>:&nbsp;MicroStrategy experienced a 2.73% increase in pre-market trading early Friday morning, following a significant 16% drop on Thursday, according to&nbsp;<a href="https://pro.benzinga.com/">Benzinga Pro</a> on Friday.</p>
<p>The company&#8217;s stock closed 16% lower at $397.28 on Thursday, reflecting the volatility linked to&nbsp;<strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). As of 6:25 am ET on Friday,&nbsp;Bitcoin was trading at $98,608.30, with some experts predicting it could soon hit $100,000.</p>
<p>MicroStrategy&nbsp;holds over 150,000 Bitcoins, positioning itself as a leveraged play on the cryptocurrency&#8217;s fluctuations. This strategy has inadvertently exposed numerous&nbsp;institutional and retail investors to&nbsp;the unpredictable nature of Bitcoin&#8217;s price movements, despite their potential lack of interest in cryptocurrency investments.</p>
<p><strong>See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></strong></p>
<p><strong>Why It Matters</strong>: Recently, MicroStrategy completed a <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42126020/whats-going-on-with-microstrategy-stock-after-the-bell">significant financial maneuver</a>, announcing the completion of its offering of 0% convertible senior notes due 2029. The aggregate principal amount of the notes sold in the offering was $3 billion, including an additional $400 million aggregate principal amount of notes issued pursuant to an option to purchase.</p>
<p>However, <strong>Galaxy Digital Holdings Ltd</strong>. CEO <strong>Mike Novogratz </strong>recently warned that<a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead"> Bitcoin‘s &#8220;inevitable&#8221; surge</a> toward $100,000 could face a significant pullback due to excessive market leverage.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/11/42081589/tesla-electric-offers-unlimited-overnight-charging-for-just-5-a-month-as-ev-giant-races-toward-500k-sales-target?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Electric Offers Unlimited Overnight Charging For Just $5 A Month As EV Giant Races Toward 500K Sales Target</a></strong></li>
</ul>
<p><strong><em>Disclaimer</em></strong><em>: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.</em></p>
<p><em>Image via Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Pre-Market Outlook

Markets

General

$BTC

MSTR

After Plunging 16%, MicroStrategy Makes Modest Recovery In Friday Pre-Market: Is There Still Hope For A $100K BTC Effect?

EYEN

Eyenovia Continues To Evaluate Broad Range Of Strategic Alternatives; Plans Additional Actions That Are Intended To Reduce Ongoing Personnel-Related Costs By Over 70%

<p>HC Wainwright &amp; Co.  analyst Robert Burns   reiterates Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Buy and maintains $17 price target.</p>


REPL

HC Wainwright & Co. Reiterates Buy on Replimune Group, Maintains $17 Price Target

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $188.49, along with a high estimate of $232.00 and a low estimate of $147.83. A negative shift in sentiment is evident as analysts have decreased the average price target by 42.15%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732276848_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Deckers Outdoor among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$218.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$232.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>JESALYN Wong</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$181.00</td>
<td>$147.83</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Adjusts</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>JESALYN Wong</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$178.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Adjusts</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Adjusts</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$1090.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Adjusts</td>
<td>Hold</td>
<td>$147.83</td>
<td>$887.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Deckers Outdoor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Deckers Outdoor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Deckers Outdoor's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Deckers Outdoor's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DECK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Deckers Outdoor analyst ratings.</strong></a></p>
<h2>About Deckers Outdoor</h2>
<p>Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Majority of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Majority of its sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. It has structured their reporting around six segments which inlcudes the wholesale operations of specific brands like UGG, HOKA, Teva, Sanuk, and Other brands, alongside a segment focused on direct-to-consumer (DTC) operations.</p>
<h3>Breaking Down Deckers Outdoor's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Deckers Outdoor showcased positive performance, achieving a revenue growth rate of <strong>20.09%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>18.48%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Deckers Outdoor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>11.28%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Deckers Outdoor's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>7.23%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Deckers Outdoor's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.12</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DECK

Expert Ratings For Deckers Outdoor

<p>6 analysts have shared their evaluations of Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Skechers USA, presenting an average target of $80.83, a high estimate of $84.00, and a low estimate of $76.00. A decline of 0.82% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732276841_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Skechers USA's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$81.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Skechers USA. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Skechers USA compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Skechers USA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Skechers USA's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SKX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Skechers USA analyst ratings.</strong></a></p>
<h2>Get to Know Skechers USA Better</h2>
<p>Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.</p>
<h3>Skechers USA: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Skechers USA's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>15.94%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Skechers USA's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.23%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.5%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Skechers USA's ROA excels beyond industry benchmarks, reaching <strong>2.33%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Skechers USA's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.48</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Skechers USA Through Analyst Insights

<p>Throughout the last three months, 6 analysts have evaluated Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $76.83, with a high estimate of $90.00 and a low estimate of $64.00. This current average reflects an increase of 1.99% from the previous average price target of $75.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732276834_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Root's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas McJoynt-Griffith</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Root. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Root compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Root's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Root's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ROOT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Root analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Root</h2>
<p>Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.</p>
<h3>Root's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Root showcased positive performance, achieving a revenue growth rate of <strong>165.13%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>7.46%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Root's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>13.69%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Root's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.49%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Root's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.65</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ROOT

Analyst Scoreboard: 6 Ratings For Root

<p>Analysts' ratings for Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $48.75, with a high estimate of $50.00 and a low estimate of $45.00. This upward trend is evident, with the current average reflecting a 1.04% increase from the previous average price target of $48.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732276827_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Steven Madden. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steven Madden. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steven Madden compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Steven Madden's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Steven Madden's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SHOO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Steven Madden analyst ratings.</strong></a></p>
<h2>Get to Know Steven Madden Better</h2>
<p>Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its own stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.</p>
<h3>Steven Madden: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Steven Madden's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>13.02%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Steven Madden's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.85%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Steven Madden's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.73%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Steven Madden's ROA excels beyond industry benchmarks, reaching <strong>3.9%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Steven Madden's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.19</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SHOO

Forecasting The Future: 4 Analyst Projections For Steven Madden

<p>Across the recent three months, 9 analysts have shared their insights on Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Flowserve, revealing an average target of $62.22, a high estimate of $69.00, and a low estimate of $52.00. This upward trend is evident, with the current average reflecting a 7.81% increase from the previous average price target of $57.71.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732276817_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Flowserve's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Saree Boroditsky</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Flowserve. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Flowserve compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Flowserve's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Flowserve analyst ratings.</strong></a></p>
<h2>About Flowserve</h2>
<p>Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. In addition, Flowserve has a network of Quick Response Centers to provide aftermarket equipment services. The aftermarket services help customers with installation, diagnostics, repair, and retrofitting. Sales are roughly split across many regions, with North America and Europe contributing the majority of total revenue.</p>
<h3>Key Indicators: Flowserve's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Flowserve's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.5%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Flowserve's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>5.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.9%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Flowserve's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.12%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Flowserve's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.7</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 9 Analyst Ratings Have To Say About Flowserve

<p>During the last three months, 11 analysts shared their evaluations of Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.64, a high estimate of $16.00, and a low estimate of $8.00. Observing a 21.88% increase, the current average has risen from the previous average price target of $8.73. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732276810_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Under Armour. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Will Gaertner</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Under Armour. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Under Armour compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Under Armour's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Under Armour's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UAA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Under Armour analyst ratings.</strong></a></p>
<h2>Get to Know Under Armour Better</h2>
<p>Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.</p>
<h3>Breaking Down Under Armour's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Under Armour's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-10.7%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Under Armour's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.18%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Under Armour's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.96%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Under Armour's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.64%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Under Armour's debt-to-equity ratio is below the industry average at <strong>0.67</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 11 Analyst Evaluations For Under Armour

FFWM

First Foundation Says Ceo Scott F. Kavanaugh Retires, Appoints Thomas C. Shafer As Successor

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy and maintains $50 price target.</p>


PTGX

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $50 Price Target

<p>Buckle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.84 by 4.76 percent. This is a 15.38 percent decrease over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $293.62 million which beat the analyst consensus estimate of $286.02 million by 2.66 percent. This is a 3.24 percent decrease over sales of $303.46 million the same period last year.</p>


Buckle Q3 EPS $0.88 Beats $0.84 Estimate, Sales $293.62M Beat $286.02M Estimate

<p>HC Wainwright &amp; Co.  analyst Robert Burns   reiterates Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) with a Neutral and maintains $12 price target.</p>


ZYME

HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target

<ul>
<li>On Thursday, November 21, U.S. markets closed higher, with the Dow climbing 461 points, the S&amp;P 500 adding 32 points, and the Nasdaq edging up by 6 points. Salesforce led the Dow with solid gains, while Nvidia advanced on strong earnings despite tempered growth projections. Alphabet faced a sharp decline following antitrust pressures from the Justice Department.</li>
<li>According to economic data, U.S. existing home sales rose by 3.5% in October to an annualized 3.96 million. The Philadelphia Fed Manufacturing Index dropped to -5.5 in November, missing market expectations of 8. Initial jobless claims fell by 6,000 to 213,000 for the week ending November 16.</li>
<li>Most S&amp;P 500 sectors rose Thursday, led by utilities, financials, and consumer staples, while consumer discretionary and communication services lagged.</li>
<li>The Dow Jones Industrial Average was up 1.06% and closed at 43,870.35, the S&amp;P 500 gained 0.53% to 5,948.70, and the Nasdaq Composite rose 0.03% to finish at 18,972.42.</li>
</ul>
<p><strong>Asia Markets Today</strong></p>
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 gained 0.84% and ended the session at 38,321.00, led by gains in the Gas &amp; Water, Transportation Equipment, and Banking sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.85% and ended the day at 8,393.80, led by gains in the Energy, Utilities and Healthcare sectors.</li>
<li>India&#8217;s Nifty 50 rose 2.25% to 23,875.70, and Nifty 500 gained 1.79%, closing at 22,210.40, led by gains in the Real Estate, Technology, and Public Sector Undertakings sectors.</li>
<li>China&#8217;s Shanghai Composite declined 3.06% to close at 3,267.19, and the Shenzhen CSI 300 fell 3.10%, finishing the day at 3,865.70.</li>
<li>Hong Kong&#8217;s Hang Seng fell 1.89% and closed the session at 19,229.97.</li>
</ul>
<p><strong>Eurozone at 06:00 AM ET</strong></p>
<ul>
<li>The European STOXX 50 index was down 0.25%.</li>
<li>Germany&#8217;s DAX slid 0.03%.</li>
<li>France&#8217;s CAC declined 0.19%.</li>
<li>FTSE 100 index traded higher by 0.74%</li>
</ul>
<p><strong>Commodities at 06:00 AM ET</strong></p>
<ul>
<li>Crude Oil WTI was trading higher by 0.06% at $70.14/bbl, and Brent was up 0.09% at $74.27/bbl.</li>
<li>Oil prices gained this week as Ukraine tensions escalated, raising concerns over supply disruptions, and Chinese imports showed signs of increasing.</li>
<li>Natural Gas rose 0.45% to $3.351.</li>
<li>Gold was trading higher by 0.78% at $2,672.45, Silver was up 0.35% to $31.115, and Copper fell 0.83% to $4.1210.</li>
</ul>
<p><strong>U.S. Futures at 06:00 AM ET</strong></p>
<p>Dow futures declined 0.17%, S&amp;P 500 futures were down 0.28% and Nasdaq 100 futures fell 0.40%.</p>
<p><strong>Forex at 06:00 AM ET</strong></p>
<p>The U.S. dollar index gained 0.33% to 107.32, the USD/JPY was down 0.08% to 154.39, and the USD/AUD rose 0.17% to 1.5387. The dollar hit a 13-month high.</p>
<p><em>Image via Shutterstock</em></p>


Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Mostly In Red; Dollar Hits 13-Month High - Global Markets Today While US Slept

Tapestry Announces Agreements For $2B Accelerated Share Repurchase Program; Final Settlement Is Expected To Occur By Q1 FY26 Ending September 27, 2025

<p>This approval is based on objective response rate (ORR) and median duration of response (DOR) results from the Phase 2 LITESPARK-004 trial and is the 17th approval of WELIREG for these patients globally.</p>


Merck Says National Medical Products Administration in China Has Approved WELIREG (Belzutifan), For Treatment Of Adult Patients With Von Hippel-Lindau Disease

TD Cowen analyst Marc Frahm has maintained their bullish stance on RVMD stock, giving a Buy rating on November 4. Marc Frahm has given his Buy rati...

Revolution Medicines: Strong Buy Rating Backed by Financial Stability and Promising Cancer Treatment Advances

Revolution Medicines, Inc. ( ($RVMD) ) has released its Q3 earnings. Here is a breakdown of the information Revolution Medicines, Inc. presented to...

Revolution Medicines Reports Q3 2024 Results and Progress

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS – Research Report), Revolution Medic...

Analysts' Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Revolution Medicines (RVMD – Research Report). The associated price tar...

Revolution Medicines: Strong Financial Position and Upcoming Clinical Milestones Justify Buy Rating with Increased Price Target

In a report released today, Ami Fadia from Needham maintained a Buy rating on Revolution Medicines (RVMD – Research Report), with a price target of...

Optimistic Growth Prospects for Revolution Medicines with Promising Data Updates and Increased Price Target

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a price tar...

Stifel Nicolaus Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research Report), ...

Promising Outlook for Revolution Medicines: Buy Rating Backed by Strong RAS ON Inhibitor Progress and Financial Stability

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Revolution Medicines (RVMD – Research Report)...

Revolution Medicines (RVMD) Receives a Buy from Bank of America Securities

Jefferies initiated coverage of Erasca (ERAS) with a Buy rating and $6 price target. The firm sees appeal in the company's valuation, citing the co...

Erasca initiated with a Buy at Jefferies

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

AGCO

ALRM

AMZN

ARMK

ASND

AVGO

BRBR

CVNA

CYBR

DAWN

DELL

DKNG

ERAS

EWTX

GWRE

ISRG

KLAC

KVUE

LEGN

MNDY

MSFT

NTRA

PODD

ROIV

RVMD

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VICI

XENE

Health Care

Press Releases

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

Earnings

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Comments

Revolution Medicines

매도 수량

Revolution Medicines (NASDAQ:RVMD) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌